GREENWOOD VILLAGE, Col. (
) -- Instead of addressing questions about its drug-development plans posed by critics,
(AMPE - Get Report)
blames short sellers for trying to destroy the company.
On Friday, Ampio Chairman and CEO Mike Macaluso accused
of trying to intentionally "damage the existing shareholders by triggering a downward pressure on their stock holdings."
In his statement, Macaluso also links Dredly with Peter Bortel, a hedge fund manager who wrote a series of
negative articles about Ampio
in 2011. While writing about Ampio, Bortel was also "working with a group of short selling speculators" and under investigation and a cease-and-desist order from the Securities and Exchange Commission, Macaluso claims.
This all sounds very sinister, which is what Macaluso wants investors to believe. In reality, Ampio's response is just a lazy, diversionary tactic. By attacking the credibility of its critics, the company hopes investors won't realize or care that responses to
legitimate questions remain unanswered
Bortel's Pegasus Investment Management did get into some hot water with the SEC in 2011, but it was over the erroneous classification of $90,000 in cash payments related to futures trades. The SEC's
cease-and-desist order can be read here
and has nothing at all to do with short selling or Ampio.
Dredly and Bortel are right to question the legitimacy of Ampio's drugs. I've done the same thing.
In April 2012, Ampio claimed to have
reached agreement with regulatory officials in Australia
that would allow the company to seek approval for Zertane in June 2012.
I warned investors to be wary of
Ampio's misleading claims about Zertane
June 2012 came and went without a follow-up announcement from Ampio about filing Zertane for approval in Australia. Instead, Ampio issued a press release conceding the company would be
required to conduct two, phase III studies of Zertane
before seeking approval in the U.S.
One year later, Ampio has still not submitted an approval application for Zertane in Australia, nor has the company started the two phase III studies required before it can seek approval in the U.S. Repeated promises by Ampio management to find a partner for Zertane have also gone unfulfilled.
Ampio spokesman Rick Giles, reached for comment via email Friday, didn't why the company has been unable to meet any of its Zertane timelines.